Fusobacterium nucleatum
Morphology |
Anaerobic, gram-negative bacilli, non-sporulating bacteria. Cells are slender with
tapered ends or pleomorphism.
|
---|---|
Disease |
Pharyngotonsillitis, peritonsillar abscesses, Lemierre Disease, sepsis, metastastic abscesses in lungs, liver, joints and pleural spaces, intra-abdominal and pulmonary infections. Most prevalent species implicated in adverse pregnancy outcomes. |
Zoonosis |
Yes, through animal bites or handling infected animals with opens wounds/sores.
|
Host Range |
Humans and animals.
|
---|---|
Modes of Transmission |
Contact with mucous membranes, penetration through skin, transfer of bodily fluids,
ingestion.
|
Signs and Symptoms |
Redness, swelling, pain, fever.
|
Infectious Dose | Unknown. |
Incubation Period |
Unknown.
|
Prophylaxis | None. |
---|---|
Vaccines | None. |
Treatment |
Surgical drainage and/or treatment with appropriate antibiotics. If infection is discovered
to be caused by F. nucleatum or F. necrophorum, treatment should be started promptly
as these two species have been linked to deaths as a result of severe cases of Lemierre’s
disease.
|
Surveillance | Monitor for symptoms. |
MSU Requirements | Report any exposures |
Laboratory Acquired Infections (LAIs) | Cases have been reported.
|
---|---|
Sources |
Feces, necrotic tissues, respiratory tract tissues, urogenital specimens, gut contents,
litter, and soil. Cultures, frozen stocks, other samples described in IBC protocol.
|
BMBL:
|
https://www.cdc.gov/labs/BMBL.html |
---|---|
Canada PSDS:
|
|
NIH Guidelines:
|
Risk Group 2
|
Agents that are associated with human disease which is rarely serious and for which preventive or therapeutic interventions are often available. |
---|---|
BSL2
|
For all procedures involving suspected or known infectious specimen or cultures.
|
ABSL2
|
For all procedures involving infected animals
|
Small
|
Notify others working in the lab. Remove PPE and don new PPE. Cover area of the spill
with absorbent material and add fresh 1:10 bleach:water. Allow 20 munutes (or as directed)
of contact time. After 20 minutes, cleanup and dispose of materials.
|
---|---|
Large
|
|
Mucous membrane
|
Flush eyes, mouth, or nose for 5 minutes at eyewash station.
|
---|---|
Other Exposures
|
Wash area with soap and water for 5 minutes.
|
Reporting |
Immediately report incident to supervisor, complete a First Report of Injury form, and submit to Safety and Risk Management.
|
Medical Follow-up
|
During business hours: Bridger Occupational Health 3406 Laramie Drive. Weekdays 8am -6pm. Weekends 9am-5pm
After business hours: Bozeman Deaconess Hospital Emergency Room 915 Highland Blvd Bozeman, MT |
Disinfection |
Susceptible to 1:10 bleach:water, 70 % ethanol
|
---|---|
Inactivation |
Inactivated by moist heat (60 minutes at 121oC) and dry heat (1 hour at 160-170oC), gamma irradiation.
|
Survival Outside Host |
Persists in soil for up to 18 weeks; survives in fecal slurry up to 24 hours.
|
Minimum PPE Requirements
|
Lab coat, disposable gloves, safety glasses, closed toed shoes, long pants
|
---|---|
Additional Precautions
|
Additioanl PPE may be required depending on lab specific SOPs and IBC Protocol. |